Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOX+Bevacizumab and XELIRI+Bevacizumab Alternation in Advanced Colorectal Cancer
NCT03511183Phase 2Unknown
- Sponsor
- Harbin Medical University
- Start
- Mar 2018
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, oxaliplatin, irinotecan, capecitabine in colorectal cancer (CRC), sponsored by Harbin Medical University. Status: unknown.
02
Drugs
bevacizumaboxaliplatinirinotecancapecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03511183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03511183.